• 1
    Keys A. Biology of Human Starvation. Minneapolis: University of Minnesota Press; 1950.
  • 2
    Stunkard AJ. The dieting depression; incidence and clinical characteristics of untoward responses to weight reduction regimens. Am J Med 1957;23: 7786.
  • 3
    Chaput JP, Arguin H, Gagnon C, Tremblay A. Increase in depression symptoms with weight loss: association with glucose homeostasis and thyroid function. Appl Physiol Nutr Metab 2008;33:8692.
  • 4
    Pagoto S, Bodenlos JS, Kantor L et al. Association of major depression and binge eating disorder with weight loss in a clinical setting. Obesity (Silver Spring) 2007;15:25572559.
  • 5
    Ludman E, Simon GE, Ichikawa LE et al. Does depression reduce the effectiveness of behavioral weight loss treatment Behav Med 2010;35: 126134.
  • 6
    McFarlane T, Polivy J, McCale RE. Help, not harm: psychological foundation for a nondieting approach toward health. J Soc Issues 1999;55:261276.
  • 7
    Campos P. The Obesity Myth: Why America's Obsession with Weight is Hazardous to Your Health. New York: Gotham Books; 2005.
  • 8
    Brinkworth GD, Buckley JD, Noakes M, Clifton PM, Wilson CJ. Long-term effects of a very low-carbohydrate diet and a low-fat diet on mood and cognitive function. Arch Intern Med 2009;169:18731880.
  • 9
    Hainer V, Hlavatá K, Gojová M et al. Hormonal and psychobehavioral predictors of weight loss in response to a short-term weight reduction program in obese women. Physiol Res 2008;57 Suppl 1:S17S27.
  • 10
    Wadden TA, Foster GD, Letizia KA. One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. J Consult Clin Psychol 1994;62:165171.
  • 11
    Rubin RR, Knowler WC, Ma Y et al.; Diabetes Prevention Program Research Group. Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. Diabetes Care 2005;28:830837.
  • 12
    Clark MM, Niaura R, King TK, Pera V. Depression, smoking, activity level, and health status: pretreatment predictors of attrition in obesity treatment. Addict Behav 1996;21:509513.
  • 13
    Marcus MD, Wing RR, Guare J, Blair EH, Jawad A. Lifetime prevalence of major depression and its effect on treatment outcome in obese type II diabetic patients. Diabetes Care 1992;15:253255.
  • 14
    Faulconbridge LF, Wadden TA, Berkowitz RI et al. Changes in symptoms of depression with weight loss: results of a randomized trial. Obesity (Silver Spring) 2009;17:10091016.
  • 15
    Linde JA, Jeffery RW, Levy RL et al. Binge eating disorder, weight control self-efficacy, and depression in overweight men and women. Int J Obes Relat Metab Disord 2004;28:418425.
  • 16
    Jeffery RW, Sherwood NE, Brelje K et al. Mail and phone interventions for weight loss in a managed-care setting: Weigh-To-Be one-year outcomes. Int J Obes Relat Metab Disord 2003;27:15841592.
  • 17
    Delahanty LM, Meigs JB, Hayden D, Williamson DA, Nathan DM; Diabetes Prevenion Program (DPP) Research Group. Psychological and behavioral correlates of baseline BMI in the diabetes prevention program (DPP). Diabetes Care 2002;25:19921998.
  • 18
    Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306313.
  • 19
    Tate DF, Wing RR, Winett RA. Using Internet technology to deliver a behavioral weight loss program. JAMA 2001;285:11721177.
  • 20
    Tsai AG, Wadden TA, Sarwer DB et al. Metabolic syndrome and health-related quality of life in obese individuals seeking weight reduction. Obesity (Silver Spring) 2008;16:5963.
  • 21
    Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 2001;161:218227.
  • 22
    Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:10691078.
  • 23
    Egede LE, Zheng D. Independent factors associated with major depressive disorder in a national sample of individuals with diabetes. Diabetes Care 2003;26:104111.
  • 24
    Look AHEAD Research Group, Pi-Sunyer X, Blackburn G et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007;30:13741383.
  • 25
    Williamson DA, Rejeski J, Lang W et al.; Look AHEAD Research Group. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med 2009;169:163171.
  • 26
    US Food and Drug Administration Advisory Committee. FDA Briefing Document: Zimulti (rimonabant) Tablets, 20 mg. Rockville: FSA; Assessed 6 August 2007). 2007.
  • 27
    Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:17061713.
  • 28
    Ryan DH, Espeland MA, Foster GD et al.; Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610628.
  • 29
    Wadden TA, West DS, Neiberg RH et al.; Look AHEAD Research Group. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring) 2009;17:713722.
  • 30
    Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention . Diabetes Care 2002;25:21652171.
  • 31
    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561571.
  • 32
    Lustman PJ, Clouse RE, Griffith LS, Carney RM, Freedland KE. Screening for depression in diabetes using the Beck Depression Inventory. Psychosom Med 1997;59:2431.
  • 33
    Beck AT, Steer, RA. Beck Depression Inventory Manual. In: Corporation TP (In: San Antonio: Harcourt Brace & Company; 1987.
  • 34
    Spitzer RL, Yanovski S, Marcus MD. Binge Eating Disorder Clinical Interview. Pittsburgh, PA: Behavioral Measurement Database Services; 1994.
  • 35
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473483.
  • 36
    Tang TZ, DeRubeis RJ. Sudden gains and critical sessions in cognitive-behavioral therapy for depression. J Consult Clin Psychol 1999;67: 894904.
  • 37
    Rubin RR, Ma Y, Marrero DG et al.; Diabetes Prevention Program Research Group. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008;31:420426.
  • 38
    Wadden TA, Berkowitz RI, Womble LG et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:21112120.
  • 39
    Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001;286:13311339.
  • 40
    Gorin AA, Niemeier HM, Hogan P et al.; Look AHEAD Research Group. Binge eating and weight loss outcomes in overweight and obese individuals with type 2 diabetes: results from the Look AHEAD trial. Arch Gen Psychiatry 2008;65:14471455.
  • 41
    Department of Health and Human Service, Public Health Service, Food and Drug Administration Center for Drug Evaluation and Research Memorandum, 16 November 2006: Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). Appendix 2: Request to Sponsors – Advice for the pharmaceutical industry in exploring their placebo-controlled clinical trials databases for suicidality and preparing data sets for analysis by FDA. <http:www.fda.govohrmsdocketsac06briefing2006-4272b1-01-fda.pdf>